Johnson & Johnson: Arthritis, Psoriatic trials

The registry lists 38 Arthritis, Psoriatic studies with Johnson & Johnson as lead sponsor. 7 are open to participants now and 13 have results posted.

Early Phase 1 1Phase 1 2Phase 2 4Phase 3 14Phase 4 4No phase 13(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Remotely Conducted Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA TherapeuticallyRecruitingNCT07654751Phase 4
• A Study of Guselkumab Treatment Persistence in Psoriatic Arthritis ParticipantsRecruitingNCT07532226
• A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic ArthritisRecruitingNCT07321873Phase 2
• A Study of Guselkumab in Participants With Psoriatic Arthritis (PsA) in a Real-World SettingRecruitingNCT07220824
• A Study of Guselkumab Administered Subcutaneously in Treatment of Indian Participants With Psoriatic Arthritis (PsA)RecruitingNCT07141004Phase 4
• A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic ArthritisRecruitingNCT06807424Phase 3
• A Long-term Extension (LTE) Study of Guselkumab in Pediatric ParticipantsRecruitingNCT06663332Phase 3
• A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoriatic ArthritisCompletedNCT05071664Phase 2Results posted
• Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha AgentCompletedNCT04936308Phase 3Results posted
• A Study of Guselkumab in Participants With Active Psoriatic ArthritisActive, not recruitingNCT04882098Phase 3Results posted
• A Study of Golimumab in the Treatment of Indian Participants With Active Spondyloarthropathy of Ankylosing Spondylitis or Psoriatic ArthritisCompletedNCT03733925Phase 4Results posted
• A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti -Tumor Necrosis Factor (TNF) Alpha Agent(s)CompletedNCT03162796Phase 3Results posted
• A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic ArthritisCompletedNCT03158285Phase 3Results posted
• Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Active Psoriatic Arthritis (PsA)CompletedNCT02319759Phase 2Results posted
• A Study of Golimumab in Participants With Active Psoriatic ArthritisCompletedNCT02181673Phase 3Results posted
• A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF AgentsCompletedNCT01077362Phase 3Results posted
• A Study of the Safety and Effectiveness of Ustekinumab in Patients With Psoriatic ArthritisCompletedNCT01009086Phase 3Results posted
• An Observational Study of Infliximab Injection in Ankylosing Spondylitis, Rheumatoid Arthritis, Psoriatic Arthritis and Psoriasis ParticipantsCompletedNCT00760669Results posted
• An Effectiveness and Safety Study of CNTO 1275 in Patients With Active Psoriatic ArthritisCompletedNCT00267956Phase 2Results posted
• A Study of the Safety and Efficacy of Golimumab in Patients With Active Psoriatic ArthritisCompletedNCT00265096Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic ArthritisActive, not recruitingNCT06878404Phase 3
• A Study of Ustekinumab in Pediatric Participants (U-POPS) With Juvenile Psoriatic Arthritis or PsoriasisCompletedNCT05252533Phase 1
• A Long-term Extension Study of Ustekinumab in Pediatric ParticipantsActive, not recruitingNCT05092269Phase 3
• A Study of Guselkumab and Risankizumab in Healthy Participants and Participants With Psoriatic ArthritisTerminatedNCT05083078Phase 1
• A Study of Guselkumab and Interleukin-17 (IL-17) Inhibitor Therapies in Participants With Psoriatic Arthritis in Routine Clinical PracticeActive, not recruitingNCT05049798
• A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial DiseaseActive, not recruitingNCT04929210Phase 4
• A Study of Guselkumab in Participants With Active Psoriatic Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Alpha (Anti-TNF Alpha) TherapyCompletedNCT03796858Phase 3
• A Study to Characterize Profile of Participant With Psoriatic Arthritis Depending on Whether Their Disease is Managed by a Dermatologist or by a Rheumatologist, and Starting UstekinumabCompletedNCT03336281
• Tracking Biologics Along the Silk RoadCompletedNCT03006198
• A Study on Assessment of STELARA and Tumor Necrosis Factor Alpha Inhibitor Therapies in Participants With Psoriatic ArthritisCompletedNCT02627768
• A Study in Participants With Psoriatic Arthritis Attending Dermatology ClinicsCompletedNCT02470481
• A Study to Assess the Safety and Effectiveness of Golimumab in Filipino Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing SpondylitisWithdrawnNCT01692457
• Golimumab Safety and Surveillance Program Using the Ingenix NHI DatabaseCompletedNCT01081717
• Biologic Treatment Registry Across CanadaCompletedNCT00741793
• Analysis of Birth Outcomes of Swedish, Danish and Finnish Women Exposed to Remicade With Inflammatory Bowel Disease, Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and PsoriasisCompletedNCT00658827
• A Study to Test the Design, Functionality, and Ergonomic Features of the AutoinjectorCompletedNCT00643526Early Phase 1
• Psoriasis Longitudinal Assessment and RegistryActive, not recruitingNCT00508547
• A Study of the Safety and Effectiveness of Infliximab for the Treatment of Psoriatic ArthritisCompletedNCT00051623Phase 3